1. Introduction {#sec0005}
===============

Coronavirus disease 19 (COVID-19) is a pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). A recent paper with data as of April 7th from the Tibet, Bolivia and Ecuador suggests that high-altitude (HA) may provide protection from pathogenesis of SAR-CoV-2 infection ([@bib0005]). A more recent paper with data from Cusco, Peru, concluded that the disease symptoms are not different in residents at high altitude ([@bib0060]).

By April 28, 2020 for Cusco, Peru (3414 m) was observed 0.5 % of case-fatality rate for the native population. This value is lower that the Peruvian case-fatality rate of 2.8 **%** ([@bib0060]). Although, the figures may support the hypothesis that life in HA may provide some protection from severe COVID-19, it is necessary to be cautious before reach to a conclusion ([@bib0010]). In fact, analysis of infection and mortality by COVID-19 in Peru shows a different scenario.

The current study has been designed to determine COVID-19 cases, deaths by COVID-19 and case-fatality rates in Peru in an altitude range from 3 to 4,342 m above sea level.

2. Material and methods {#sec0010}
=======================

The COVID-19 database of the Open Data website of Peru (<https://www.datosabiertos.gob.pe/group/datos-abiertos-de-covid-19>) obtained on June 14, 2020 was analyzed to study COVID-19 deaths, and positive to SARS-CoV-2. Data of population and surface areas of provinces, and altitude of capital of provinces in Peru was obtained from the Peruvian Center for Planning CEPLAN website (<https://www.ceplan.gob.pe/informacion-sobre-zonas-y-departamentos-del-peru/>). By June 13, 2020, in Peru were recorded 225,132 SARS-CoV-2 positive cases and 6498 deaths. From all identified positive cases, 58.1 % were males (N = 130,913), and from all deaths, 71.0 % were men (N = 4619).

We explored distinct linear models to assess the relation of the reported positive cases and deaths, by sex and sex ratio, at provincial levels, with altitudes of 185 capitals of provinces with altitudes ranging from 3 to 4342 m. (N = 185).

Case-fatality rates were assessed at each level of altitude. The case-fatality rate is the proportion of persons with a particular condition (cases) who die from that condition. It is a measure of the severity of the condition. The formula is: Number of cause-specific deaths among the incident cases divided by Total number of incident cases\*100 ([@bib0015]).

3. Results {#sec0015}
==========

By June 13, 2020, the cumulative case-fatality rate for Peru was 2.33 %. In Cusco city (3414 m) case-fatality rate was 0.52 % similar to that observed by [@bib0060]. However, assessing other cities as Cajatambo (3382 m), Jauja (3389 m), and Puno (3848 m), the case-fatality rates were 14.29 %, 4.71 % and 2.17 %, respectively. These individual data seem to suggest that there is not a trend for reduced case-fatality rate at HA.

We have observed that, the number of cases positive for COVID-19 appears to decrease with altitude of residence ([Fig. 1](#fig0005){ref-type="fig"} A). The same pattern is observed in males and females even after adjustment by population density ([Fig. 1](#fig0005){ref-type="fig"}B and C). The sex ratio (male/female) for positive cases of COVID-19 is maintained at any altitude of residence ([Fig. 1](#fig0005){ref-type="fig"}D). This might mean that the same proportion of men related to females have risk of being infected with COVID-19 independent of the altitude of residence.Fig. 1Number of Cases (Log Positive counts/population density) according to altitude (meters) of residence in Peru: (A) All positive cases, (B) Male cases, (C) Female cases, (D) Male/female ratio.Fig. 1

The numbers of deaths are significantly lower as altitude of residence increase. This is observed in both sexes assessed together or after analyzing men and women separately ([Fig. 2](#fig0010){ref-type="fig"} A--C). The more interesting finding is that women loss protection against death for COVID-19 at HA ([Fig. 2](#fig0010){ref-type="fig"}D). In fact, as altitude of residence increase, more women die reducing the proportion of male/female deaths as altitude increases (p \< 0.01).Fig. 2Number of Deaths by COVID-19 (Log deaths/population density) according to altitude (meters) of residence in Peru. A) All deaths, (B) Male deaths, (C) Female deaths, (D) Male/female ratio.Fig. 2

Another important finding from our study is that the cumulative case-fatality rate (cumulative deaths/cumulative positive cases) by COVID-19 does not appear to change with altitude of residence ([Fig. 3](#fig0015){ref-type="fig"} ). This does not support the suggestion that people from the highlands might be protected from death after COVID-19 infection. This is significant since our analysis includes a broad range of altitudes (from 3 to 4,342 m). According to the data source, the positive cases have been determined by PCR or antibody tests, and the data has been adjusted by demographic density where appropriate.Fig. 3Cumulative case-fatality rate by COVID-19 in Peru according to altitude of residence.Fig. 3

4. Discussion {#sec0020}
=============

SARS-CoV-2 requires for replication an interaction with the human angiotensin converting enzyme 2 (ACE2) receptor, which plays an essential role in cell entry together with transmembrane serine protease 2 (TMPRSS2). SARS-CoV-2 infection occurs through binding and internalization of the viral spike protein to angiotensin converting enzyme 2 (ACE2) on the host cell membrane ([@bib0025]).

Elevated ACE2 expression increases sensitivity to coronavirus infection. Individuals may be exceedingly susceptible to COVID-19 due to concomitant high preexisting ACE2 expression and low baseline cytotoxic lymphocyte levels in the lung ([@bib0030]). This may occur at older than in younger ages and in males than in females, and at low than at high altitudes.

Expression of alveolar epithelial cells of ACE2 and TMPRSS2 is higher in adults compared to young lungs. This may suggest reduced viral entry and replication in the lung epithelial cells in children compared to adults ([@bib0110]). Then, children may be protected from serious pulmonary damage in part by the decreased expression of ACE 2 receptors and other proteins that are essential for viral entry into the respiratory epithelium ([@bib0080]). ACE2 was highly expressed in patients with comorbidities suggesting these are in a higher risks of developing severe COVID-19 ([@bib0090]).

Males are more susceptible to SARS-CoV-2 than females, with males 65 % more likely to die from the infection than females ([@bib0035]). In Peru, 59 % of deaths by COVID19 are in males. Worldwide, according the World Health Organization (WHO) from all cases about 1.7 % of women who contract the virus will die compared with 2.8 % of men ([@bib0035]). In Peru, we have observed that case-fatality rate in women is 1.65 %, and in men 2.84 %, similar to that described in the literature. It is possible that high levels of androgen in males explain this difference in rate of infection and case-fatality rate. ACE 2 levels and internalization of recombinant spike receptor binding domain (Spike-RBD) in hESC-derived cardiac cells and human alveolar epithelial cells may be reduced with a 5 alpha reductase inhibitor ([@bib0040]).

The severity of COVID-19 worsens with advancing age for both sexes, possibly due to a dysregulation of the immune response by changes in sex-hormones occurring with age ([@bib0065]; [@bib0075]). It has also been suggested that the number of active X-chromosomes in synergy with sex hormones, may account for the low risk and better prognosis of SARS-CoV-2 infection in females ([@bib0035]).

Gonadectomy did not affect disease outcome in male mice, whilst ovariectomy or estrogen receptor antagonists caused increased mortality in females after SARS-CoV infection ([@bib0020]). Ovariectomy reduces interferon gamma, a compound contributing to the cell-mediated immunity ([@bib0070]). At HA has been observed that women have increased values of ratio testosterone/estradiol compared to that observed in women at low altitude ([@bib0045]). This high androgen bioactivity may explain why women at HA are less protected to die that women from lowlands in the presence of COVID-19 infection.

At HA, the low rate of infection with COVID-19 may be explained at least from two different mechanisms. One of them associated to the polymorphism of the gene ACE 2. The DD genotype of ACE is a risk factor for HA maladaptation and the presence of ACE II allele carriers in a population indicate a greater ability to adapt to HA ([@bib0105]). The presence (insertion, I allele) rather than the absence (deletion, D allele) of a 287 bp fragment is associated with lower serum and tissue ACE activity ([@bib0115]). In HA settlements in both South America and India, the I allele for ACE2 exists in greater frequency ([@bib0095]). The low ACE2 activity in populations at HA may protect them against replication of the virus in the cells of the host.

The second proposed mechanism for low infection by COVID-19 at the highlands is an effect of the ultraviolet (UV) radiation on vitamin D production. Vitamin D deficiency contribute to acute respiratory distress syndrome; and that case-fatality rates increase with age and with chronic disease comorbidity, both of which are associated with lower 25(OH)D concentration ([@bib0050]). However, a study in indigenous Argentinian children showed that those living at HA had less levels of vitamin D than those living at lower altitudes ([@bib0055]).

Population located at higher latitudes have lower vitamin D ([@bib0085]), however, populations at HA located at these higher latitudes are also protected from the COVID-19 infections ([@bib0005]). It has also been suggested that UV radiation at HA could be acting as natural sanitizing reducing risk of infection ([@bib0005]). This hypothesis to be proved will require further studies.

The strength of the study is that includes cases and deaths occurred from a range of altitudes between 3 and 4342 m.

One limitation of the study is that according to the classification proposed by [@bib0100], \"patients with clear symptoms\" represent mainly severe patients (phase II) and critically ill patients (phase III), while they are asymptomatic and mildly ill (oligosymptomatic - phase I), they are mostly not reported. Then, it is not possible to conclude about severity and progression of COVID-19 based only in the study of case fatality rates. Other factors may affect the relation between the case fatality rate and the actual infection fatality rate for a specific population.

5. Conclusion {#sec0025}
=============

We confirm previous reports that infection with COVID-19 at HA is reduced. However, case-fatality rate was not modified by altitude. We have presented first evidence that female protection towards death by COVID-19 is reduced as altitude of residence increases.
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